Research · Sep 3, 2026
[CTVA] Corteva Thesis 2026: Enlist E3 Continued Share Gains + Biological/Biotech R&D Pipeline Anchor Crop Productivity Through Grain Cycle Pressure
Corteva FY2025 revenue ~$17-18B (+1-3%) with adj. EPS ~$2.80-3.20 reflecting continued grain cycle pressure (corn $4.20-4.50/bushel + soybean $11-12/bushel, both off FY2022 peak) partially offset by Enlist E3 soybean trait penetration gains + selective crop protection pricing. Major US agriculture inputs company (seeds + crop protection) spun off from DowDuPont June 2019. 2 segments: Seed ~$9-10B (~55% — Pioneer brand legacy with world-leading germplasm + traits portfolio including Enlist E3 soybeans + Qrome corn 2nd-generation insect protection + Vorceed corn 3rd-generation in commercialization 2025-2026), Crop Protection ~$8B (~45% — herbicides + insecticides + fungicides + biologicals). CEO Chuck Magro since November 2021 (joined from Nutrien Ltd. where served as CEO 2014-2021). Enlist E3 soybean penetration trajectory: ~10% FY2020 → ~25% FY2021 → ~40% FY2022 → ~50% FY2023 → ~55% FY2024 → ~58% FY2025E → ~60-62% FY2026E (share gains primarily from Bayer Roundup Ready 2 Xtend dicamba displacement following EPA dicamba application restrictions Feb 2024 ruling vacating dicamba labels). R&D spend ~$1.4B/yr (highest among major agriculture inputs companies) targeting $5B+ cumulative new product revenue by FY2030. Capital return $1.45-1.95B FY2025 (dividend $0.45B + buybacks $1-1.5B). FY2026 thesis: Enlist E3 share gains + Vorceed launch + biological/biotech pipeline + Crop Protection productivity. Risks: grain prices weakness, generic competition, regulatory delays.